CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 31,415 Shares

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 31,415 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $25.03, for a total value of $786,317.45. Following the completion of the transaction, the chief executive officer owned 787,799 shares in the company, valued at $19,718,608.97. This represents a 3.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total transaction of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total transaction of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $18.33, for a total transaction of $714,870.00.

CeriBell Stock Down 2.3%

CeriBell stock opened at $24.31 on Friday. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33. The firm’s fifty day simple moving average is $19.43 and its 200-day simple moving average is $19.19. The company has a market capitalization of $933.02 million, a P/E ratio of -13.81 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Sell-side analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Trading of CeriBell

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CBLL. Wellington Management Group LLP increased its position in CeriBell by 5.5% in the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after buying an additional 4,572 shares during the period. Formula Growth Ltd. bought a new stake in shares of CeriBell in the second quarter valued at approximately $603,000. Bank of America Corp DE acquired a new stake in shares of CeriBell in the second quarter worth $4,619,000. PDT Partners LLC acquired a new stake in shares of CeriBell in the second quarter worth $1,026,000. Finally, Legal & General Group Plc bought a new position in CeriBell during the second quarter worth $53,000.

Analysts Set New Price Targets

CBLL has been the subject of several analyst reports. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday. BTIG Research lifted their price target on shares of CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Canaccord Genuity Group boosted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, CeriBell presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.40.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.